Articles
Board Retreat Topics 2023
By Mark Land, M.S., RAC, AAHP President The AAHP Board Retreat is designed to give the board the opportunity to reflect on objectives and accomplishments of the current year, as…
Read MoreAAHP Industry Reception with Walgreens’ Michael Wolf Accepting the Integrative Medicine Retailer Award
By Alissa Gould, AAHP Volunteer Communications Chair The annual AAHP Industry Reception is back for its fifth year! Mark your calendars for this small-scale networking event with a major retailer.…
Read MoreAre You Ready to Launch a Product on Amazon?
By Ray Petrick, Vice President of Sales, Boiron USA Amazon customers buy roughly 7,400 products per minute from U.S. sellers. It is a monster platform — with hundreds of millions…
Read MoreA High-Level Comparison of Homeopathic Product Regulation in the US, EU, and Canada
Two members of the AAHP Board, Mark Land and Eric Foxman, attended a June meeting with members of similar organizations from the European Union (EU), the United Kingdom (UK), and…
Read MoreSnapshots from There and Then: History of Homeopathy
In honor of AAHP’s 100th anniversary year, we’re looking back at the history of homeopathy to learn how the medical modality spread worldwide. Readers will discover startling vignettes of unexpected…
Read MoreAAHP Integrative Medicine Retailer Award: History and Philosophy
By Mark Land, M.S., RAC, AAHP President For several years now, food, drug, and mass retailers have recognized the consumer shift toward integrative health. To assist and connect with retailers…
Read More5th International Homeopathic Research Conference
By Mark Land, M.S., RAC, AAHP President The Homeopathic Research Institute (HRI) held its 5th international research conference on homeopathy in London, June 15–18, 2023. The conference theme was “cutting edge research in…
Read MoreFDA’s Center for Drug Evaluation and Research’s (CDER) Office of Compliance
By Mark Land, M.S., RAC, AAHP President The Office of Compliance (OC) shields patients from poor quality, unsafe, and ineffective drugs through compliance strategies and risk-based enforcement actions. OC makes…
Read MoreMeet Jill Furman, JD, New Director of FDA’s Office of Compliance
Drug evaluation and research help to ensure drug quality and therefore, public safety. Leading the charge in this critical mission is Jill Furman, J.D., the Director of the Office of…
Read MoreFDA Office of Compliance Annual Report FY 2022
FDA’s Office of Compliance (OC) recently published its Annual Report for Fiscal Year 2022.1 The report was introduced by Director Jill Furman. Ms. Furman took over the director’s role in…
Read More